How to Ask for GLP-1 Medications: A Comprehensive Guide

Last reviewed: June 6, 2026

Last updated: June 6, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

The most effective way to ask a clinician about GLP-1 medications is to arrive with a history rather than a product name. Prescribers are not gatekeeping a brand; they are assessing whether you fall inside a labeled population, whether anything in your history contraindicates the class, and whether the medication fits alongside everything else you take. A request framed as "here is my weight history, here are my related diagnoses, here is what I have already tried" gives them the material to answer. A request framed as "I would like Ozempic" often does not, because Ozempic has no weight-management indication.

Bring the Documentation That Decisions Are Made From

Useful material includes measured height and weight over time rather than estimates, any prior weight loss attempts and what happened with them, current medications and supplements, and a list of diagnoses that relate to weight — hypertension, dyslipidemia, prediabetes or type 2 diabetes, obstructive sleep apnea, fatty liver disease, osteoarthritis.

This is the same material a prior authorization request will need later, so gathering it once saves a second round. Plans routinely ask for a calculated body mass index consistent with the labeled population plus documented weight-related comorbid conditions.

If you have a sleep apnea diagnosis or established cardiovascular disease, say so explicitly. Those map to distinct approved indications, and a reviewer works from what is written rather than from what could reasonably be inferred.

Ask About the Indication, Not the Brand

The single most common source of friction is naming the wrong product. Ozempic and Mounjaro are type 2 diabetes products. Wegovy and Zepbound carry the weight-management indications. Rybelsus and Ozempic tablets are oral semaglutide for type 2 diabetes.

A better opening is functional: "I would like to discuss whether a medication approved for chronic weight management is appropriate for me." That invites the clinician to select the right product for your situation rather than to correct your premise first.

It also leaves room for the answer to be a different class entirely. Not everyone with a weight concern is a candidate for an incretin agent, and some people are better served by addressing a contributing medication, an untreated sleep disorder, or a thyroid problem.

Expect Questions About Contraindications

Both semaglutide and tirzepatide labels carry a boxed warning about thyroid C-cell tumors observed in rodents, and both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2. Expect to be asked about family history in some detail.

Other areas that come up routinely include a history of pancreatitis, gallbladder disease, diabetic retinopathy, severe gastroparesis, current or planned pregnancy, and concurrent insulin or sulfonylurea use, which can raise the risk of hypoglycemia.

Answer these fully even when they feel unrelated. The point of the questions is to find the small number of situations where this class is a poor fit, and an incomplete history is the most common reason a problem surfaces later rather than sooner.

Be Direct About Cost and Continuity

Ask what happens if coverage is denied, and ask it before the first prescription is written. The realistic options are an appeal, a manufacturer program, a switch to a covered alternative, or a cash-pay route — and each has a different timeline.

Continuity matters more here than in most drug classes. Randomised withdrawal trials across the GLP-1 class consistently show substantial weight regain after discontinuation, so a plan that funds three months and then stops tends to reproduce the starting point.

It is entirely reasonable to say "I can afford roughly this much per month" out loud. That constraint changes which product is a sensible starting point, and clinicians would rather know it at the first visit than at the third.

What to Ask at the Follow-Up

Reasonable follow-up questions include how tolerability will be assessed, what symptoms warrant a call rather than waiting, how progress will be measured beyond weight, and what the plan is if the response is smaller than hoped.

Ask specifically about nutrition. Appetite suppression reduces total intake, and protein adequacy plus resistance training are the standard levers for preserving lean mass during weight loss. A referral to a registered dietitian is a normal part of this.

Finally, ask what long-term looks like. The Wegovy indication includes maintaining weight reduction long term, which tells you the medication was studied and approved as an ongoing therapy rather than a short course.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

What should I say to my doctor to start the conversation?

Lead with your history rather than a brand name: measured weight over time, prior attempts and their outcomes, and any weight-related diagnoses. A useful framing is asking whether a medication approved for chronic weight management is appropriate for you. That lets the clinician choose the right product instead of first correcting a request for a diabetes-only brand.

Will my doctor refuse if I ask for a specific brand?

Not usually, but naming a diabetes-only product for a weight concern creates avoidable friction. Ozempic and Mounjaro are approved for type 2 diabetes; Wegovy and Zepbound carry the weight-management indications. Clinicians may prescribe off-label when they judge it appropriate, but doing so creates no coverage obligation and shifts the whole decision onto their judgement.

What might disqualify me from this medication class?

A personal or family history of medullary thyroid carcinoma, or Multiple Endocrine Neoplasia syndrome type 2, is a labeled contraindication for both semaglutide and tirzepatide products. Serious hypersensitivity to the drug or excipients is also a contraindication. Pancreatitis history, severe gastroparesis, gallbladder disease, retinopathy and pregnancy all prompt closer evaluation by your prescriber.

Should I mention cost at the first appointment?

Yes. Stating a realistic monthly budget changes which product is a sensible starting point and lets your clinician plan for a denial before one arrives. Because randomised withdrawal trials consistently show substantial weight regain after discontinuation, a funding plan that lasts only a few months tends to reproduce the starting point rather than improve on it.

Do I need a specialist, or will primary care prescribe these?

Primary care clinicians prescribe this class routinely, and for most people that is the right starting point because they already hold the full medication list and history. Referral to endocrinology, hepatology or sleep medicine is more likely when there is a complicating diagnosis, when previous therapy has failed, or when a specific indication such as MASH or sleep apnea is in play.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.